Postoperative serum metabolites of patients on a low carbohydrate ketogenic diet after pancreatectomy for pancreatobiliary cancer: a nontargeted metabolomics pilot study

Chang Moo Kang, Bo Kyeong Yun, Minju Kim, Mina Song, Yeon hee Kim, Sung Hwan Lee, Hosun Lee, Song Mi Lee, Seung Min Lee

Research output: Contribution to journalArticle

Abstract

A ketogenic diet is a potential adjuvant cancer therapy that limits glucose availability to tumours while fuelling normal tissues with ketone bodies. We examined the effect of a low carbohydrate ketogenic diet (LCKD) (80% kcal from fat, ketogenic ratio 1.75:1, w/w) compared to a general hospital diet (GD) on serum metabolic profiles in patients (n = 18, ≥ 19 years old) who underwent pancreatectomy for pancreatobiliary cancer. Serum samples collected preoperatively (week 0) and after the dietary intervention (week 2) were analysed with a nontargeted metabolomics approach using liquid chromatography–tandem mass spectrometry. Serum β-hydroxybutyrate and total ketone levels significantly increased after 2 weeks of LCKD compared to GD (p < 0.05). Principal component analysis score plots and orthogonal partial least squares discriminant analysis also showed significant differences between groups at week 2, with strong validation. In all, 240 metabolites differed between LCKD and GD. Pathways including glycerophospholipid and sphingolipid metabolisms were significantly enriched in the LCKD samples. LCKD decreased C22:1-ceramide levels, which are reported to be high in pancreatic cancer, while increasing lysophosphatidylcholine (18:2), uric acid, citrulline, and inosine levels, which are generally low in pancreatic cancer. Postoperative LCKD might beneficially modulate pancreatic cancer-related metabolites in patients with pancreatobiliary cancer.

Original languageEnglish
Article number16820
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Ketogenic Diet
Carbohydrate-Restricted Diet
Pancreatectomy
Metabolomics
Serum
Pancreatic Neoplasms
Neoplasms
General Hospitals
Diet
Hydroxybutyrates
Glycerophospholipids
Ketone Bodies
Inosine
Citrulline
Lysophosphatidylcholines
Sphingolipids
Metabolome
Discriminant Analysis
Principal Component Analysis
Uric Acid

All Science Journal Classification (ASJC) codes

  • General

Cite this

Kang, Chang Moo ; Yun, Bo Kyeong ; Kim, Minju ; Song, Mina ; Kim, Yeon hee ; Lee, Sung Hwan ; Lee, Hosun ; Lee, Song Mi ; Lee, Seung Min. / Postoperative serum metabolites of patients on a low carbohydrate ketogenic diet after pancreatectomy for pancreatobiliary cancer : a nontargeted metabolomics pilot study. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{20c7a4ed8253448e85a1f77a5f29d819,
title = "Postoperative serum metabolites of patients on a low carbohydrate ketogenic diet after pancreatectomy for pancreatobiliary cancer: a nontargeted metabolomics pilot study",
abstract = "A ketogenic diet is a potential adjuvant cancer therapy that limits glucose availability to tumours while fuelling normal tissues with ketone bodies. We examined the effect of a low carbohydrate ketogenic diet (LCKD) (80{\%} kcal from fat, ketogenic ratio 1.75:1, w/w) compared to a general hospital diet (GD) on serum metabolic profiles in patients (n = 18, ≥ 19 years old) who underwent pancreatectomy for pancreatobiliary cancer. Serum samples collected preoperatively (week 0) and after the dietary intervention (week 2) were analysed with a nontargeted metabolomics approach using liquid chromatography–tandem mass spectrometry. Serum β-hydroxybutyrate and total ketone levels significantly increased after 2 weeks of LCKD compared to GD (p < 0.05). Principal component analysis score plots and orthogonal partial least squares discriminant analysis also showed significant differences between groups at week 2, with strong validation. In all, 240 metabolites differed between LCKD and GD. Pathways including glycerophospholipid and sphingolipid metabolisms were significantly enriched in the LCKD samples. LCKD decreased C22:1-ceramide levels, which are reported to be high in pancreatic cancer, while increasing lysophosphatidylcholine (18:2), uric acid, citrulline, and inosine levels, which are generally low in pancreatic cancer. Postoperative LCKD might beneficially modulate pancreatic cancer-related metabolites in patients with pancreatobiliary cancer.",
author = "Kang, {Chang Moo} and Yun, {Bo Kyeong} and Minju Kim and Mina Song and Kim, {Yeon hee} and Lee, {Sung Hwan} and Hosun Lee and Lee, {Song Mi} and Lee, {Seung Min}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-53287-y",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Postoperative serum metabolites of patients on a low carbohydrate ketogenic diet after pancreatectomy for pancreatobiliary cancer : a nontargeted metabolomics pilot study. / Kang, Chang Moo; Yun, Bo Kyeong; Kim, Minju; Song, Mina; Kim, Yeon hee; Lee, Sung Hwan; Lee, Hosun; Lee, Song Mi; Lee, Seung Min.

In: Scientific reports, Vol. 9, No. 1, 16820, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Postoperative serum metabolites of patients on a low carbohydrate ketogenic diet after pancreatectomy for pancreatobiliary cancer

T2 - a nontargeted metabolomics pilot study

AU - Kang, Chang Moo

AU - Yun, Bo Kyeong

AU - Kim, Minju

AU - Song, Mina

AU - Kim, Yeon hee

AU - Lee, Sung Hwan

AU - Lee, Hosun

AU - Lee, Song Mi

AU - Lee, Seung Min

PY - 2019/12/1

Y1 - 2019/12/1

N2 - A ketogenic diet is a potential adjuvant cancer therapy that limits glucose availability to tumours while fuelling normal tissues with ketone bodies. We examined the effect of a low carbohydrate ketogenic diet (LCKD) (80% kcal from fat, ketogenic ratio 1.75:1, w/w) compared to a general hospital diet (GD) on serum metabolic profiles in patients (n = 18, ≥ 19 years old) who underwent pancreatectomy for pancreatobiliary cancer. Serum samples collected preoperatively (week 0) and after the dietary intervention (week 2) were analysed with a nontargeted metabolomics approach using liquid chromatography–tandem mass spectrometry. Serum β-hydroxybutyrate and total ketone levels significantly increased after 2 weeks of LCKD compared to GD (p < 0.05). Principal component analysis score plots and orthogonal partial least squares discriminant analysis also showed significant differences between groups at week 2, with strong validation. In all, 240 metabolites differed between LCKD and GD. Pathways including glycerophospholipid and sphingolipid metabolisms were significantly enriched in the LCKD samples. LCKD decreased C22:1-ceramide levels, which are reported to be high in pancreatic cancer, while increasing lysophosphatidylcholine (18:2), uric acid, citrulline, and inosine levels, which are generally low in pancreatic cancer. Postoperative LCKD might beneficially modulate pancreatic cancer-related metabolites in patients with pancreatobiliary cancer.

AB - A ketogenic diet is a potential adjuvant cancer therapy that limits glucose availability to tumours while fuelling normal tissues with ketone bodies. We examined the effect of a low carbohydrate ketogenic diet (LCKD) (80% kcal from fat, ketogenic ratio 1.75:1, w/w) compared to a general hospital diet (GD) on serum metabolic profiles in patients (n = 18, ≥ 19 years old) who underwent pancreatectomy for pancreatobiliary cancer. Serum samples collected preoperatively (week 0) and after the dietary intervention (week 2) were analysed with a nontargeted metabolomics approach using liquid chromatography–tandem mass spectrometry. Serum β-hydroxybutyrate and total ketone levels significantly increased after 2 weeks of LCKD compared to GD (p < 0.05). Principal component analysis score plots and orthogonal partial least squares discriminant analysis also showed significant differences between groups at week 2, with strong validation. In all, 240 metabolites differed between LCKD and GD. Pathways including glycerophospholipid and sphingolipid metabolisms were significantly enriched in the LCKD samples. LCKD decreased C22:1-ceramide levels, which are reported to be high in pancreatic cancer, while increasing lysophosphatidylcholine (18:2), uric acid, citrulline, and inosine levels, which are generally low in pancreatic cancer. Postoperative LCKD might beneficially modulate pancreatic cancer-related metabolites in patients with pancreatobiliary cancer.

UR - http://www.scopus.com/inward/record.url?scp=85075040663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075040663&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-53287-y

DO - 10.1038/s41598-019-53287-y

M3 - Article

C2 - 31727967

AN - SCOPUS:85075040663

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16820

ER -